Overview

Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Estrogens, Conjugated (USP)
Medroxyprogesterone
Medroxyprogesterone Acetate